Syndax PharmaceuticalsFRA:1T3 -0.61%25 Days Inventory is 1,166.21 as of Mar. 2026, which is 127% above its 10-year median of 514.47. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 9 warning signs investors should review. Among 638 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 90.91% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Syndax Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Syndax Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.52.
Syndax Pharmaceuticals (FRA:1T3) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Syndax Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Syndax Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Syndax Pharmaceuticals Days Inventory Related Terms
Syndax Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1T3 vs IOVA, GLUE, TYRA: Days Inventory Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals (FRA:1T3) has a Days Inventory of 1,166.21 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Syndax Pharmaceuticals and its competitors. This is 127% above median its historical median of 514.47. Over the past decade, Syndax Pharmaceuticals' Days Inventory has ranged from 161.73 to 963.47. According to the industry distribution chart, Syndax Pharmaceuticals ranks #580 out of 638 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Syndax Pharmaceuticals' Days Inventory too high?
Syndax Pharmaceuticals' current Days Inventory of 1,166.21 is 127% above median its 10-year median of 514.47. Over the past 10 years, this metric has ranged from a low of 161.73 to a high of 963.47. The Biotechnology industry median Days Inventory is 183.20. Syndax Pharmaceuticals' value of 1,166.21 is 536.6% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #580 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Days Inventory compare to IOVA and GLUE?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #580 out of 638 companies for Days Inventory. This places Syndax Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.20. Syndax Pharmaceuticals' value of 1,166.21 is 536.6% above this benchmark. Historically, Syndax Pharmaceuticals' own Days Inventory has ranged from 161.73 to 963.47 over the past decade. While the company's 10-year median is 514.47 vs. the industry median of 183.20, Syndax Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Days Inventory of 1,166.21 is 536.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Days Inventory is 1,166.21, which is 127% above median its own 10-year median of 514.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Days Inventory of 1,166.21. The current Days Inventory is 1,166.21, which is 127% above median its 10-year median of 514.47 and 536.6% above the Biotechnology industry median of 183.20. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Days Inventory is 1,166.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score
Get the complete analysis for FRA:1T3
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
